Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium

Blood (2024) 144 (Supplement 1): 5174.

https://doi.org/10.1182/blood-2024-198914

Published: 2024

Journal Articles

Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 737.

https://doi.org/10.1182/blood-2024-207953

Published: 2024

Journal Articles

The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort Study

Blood (2024) 144 (Supplement 1): 2947.

https://doi.org/10.1182/blood-2024-205581

Published: 2024

Journal Articles

Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics

Blood (2024) 144 (Supplement 1): 4267.

https://doi.org/10.1182/blood-2024-202744

Published: 2024

Journal Articles

Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 1508.

https://doi.org/10.1182/blood-2024-207045

Published: 2024

Journal Articles

Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 4261.

https://doi.org/10.1182/blood-2024-203683

Published: 2024

Journal Articles

Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Samuel J. Yates, Julian J. Weiss, Abigail Sneider, Emily Geramita, Guru Subramanian Guru Murthy, Talha Badar, Annie Im, Chenyu Lin, Wei Cheng, Eric S. Winer, Yasmin Abaza, Mark R. Litzow, Ehab L. Atallah, Alok Swaroop, Anand Ashwin Patel, Rory M. Shallis

Blood (2024) 144 (Supplement 1): 447.

https://doi.org/10.1182/blood-2024-207116

Published: 2024

Journal Articles

Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Julian J. Weiss, Samuel J. Yates, Talha Badar, Anand Ashwin Patel, Eric S. Winer, Mark R. Litzow, Wei Cheng, Chenyu Lin, Rory M. Shallis

Blood (2024) 144 (Supplement 1): 1489.

https://doi.org/10.1182/blood-2024-206670

Published: 2024

Journal Articles

Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study

Blood (2024) 144 (Supplement 1): 4580.

https://doi.org/10.1182/blood-2024-198284

Published: 2024

Journal Articles

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Blood (2024) 144 (Supplement 1): 3206.

https://doi.org/10.1182/blood-2024-211623

Published: 2024

Journal Articles

Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities

Blood (2024) 144 (Supplement 1): 4281.

https://doi.org/10.1182/blood-2024-204467

Published: 2024

Journal Articles

Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes

Blood (2024) 144 (Supplement 1): 4938.

https://doi.org/10.1182/blood-2024-209087

Published: 2024

Journal Articles

Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia

Marlise R. Luskin, Mark Alan Murakami, Julia H. Keating, Yael Flamand, Eric S Winer, Jacqueline S. Garcia, Maximilian Stahl, Richard M. Stone, Martha Wadleigh, Stella Louise Jaeckle, Ella Hagopian, David M. Weinstock, Jessica Liegel, Malgorzata McMasters, Eunice S Wang, Wendy Stock, Daniel J DeAngelo

Blood blood.2024025800.

https://doi.org/10.1182/blood.2024025800

Published: 2024

Includes: Supplemental data

Journal Articles

CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias

Rahul S. Vedula, Hannah Q. Karp, Jeremy Koob, Felicia Lim, Jacqueline S. Garcia, Eric S. Winer, Marlise R. Luskin, Gabriel Ghiaur, Annette S. Kim, Lan W. Beppu, Olga Sala-Torra, Jerald Radich, Jonathan Gootenberg, Omar Abudayyeh, Feng Zhang, R. Coleman Lindsley

Blood (2024) 144 (12): 1290–1299.

https://doi.org/10.1182/blood.2023022908

Published: 2024

Includes: Supplemental data

Journal Articles

Mini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL

Marlise R. Luskin, Shai Shimony, Julia Keating, Wendy Stock, Hanno Hock, Jacqueline S. Garcia, Maximilian Stahl, Ilene Galinksy, Rebecca Leonard, Howard Weiner, Yael Flamand, Donna S. Neuberg, Richard M Stone, Anthony G. Letai, Eric S. Winer, Marina Y. Konopleva, Nitin Jain, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2023-174269

Published: 2023

Journal Articles

Impact of Clinical and Genetic Factors on Myelofibrosis Outcomes after Allogeneic Transplantation

Mahasweta Gooptu, Haesook T. Kim, Kaina Chen, Ann Mullally, Joseph Antin, Corey Cutler, Amar H Kelkar, John Koreth, Roman M. Shapiro, Robert J. Soiffer, Daniel J. DeAngelo, Jacqueline S. Garcia, Marlise R. Luskin, Richard M Stone, Martha Wadleigh, Eric S. Winer, R. Coleman Lindsley, Vincent Ho

Blood (2023) 142 (Supplement 1): 4978.

https://doi.org/10.1182/blood-2023-178684

Published: 2023

Journal Articles

Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Eric S. Winer, Jacqueline S. Garcia, Richard M Stone, Martha Wadleigh, Marlise R. Luskin, Maximilian Stahl, Evan C. Chen, Rebecca Leonard, Alexis Noyes, Ilene Galinsky, Rashmi Deshpande, Pascal Borderies, Vincent O'Neill, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 1549.

https://doi.org/10.1182/blood-2023-186598

Published: 2023

Journal Articles

A Phase I Study of Venetoclax in Combination with Inotuzumab Ozogamicin for Relapsed or Refractory ALL in Adults

Marlise R. Luskin, Shai Shimony, Julia Keating, Yael Flamand, Jacqueline S. Garcia, Rebecca Leonard, Thomas Reardon, Taylor Robertson, Chase M Weizer, Ilene Galinsky, Donna S. Neuberg, Richard M Stone, Eric S. Winer, Anthony G. Letai, Mark Alan Murakami, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 1509.

https://doi.org/10.1182/blood-2023-174216

Published: 2023

Journal Articles

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Blood (2023) 142 (Supplement 1): 2246.

https://doi.org/10.1182/blood-2023-185315

Published: 2023

Journal Articles

Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Acute Myeloid Leukemia Patients with FLT3 Mutation

Eric S. Winer, Amit Verma, Stefanie Groepper, Katharina S. S. Götze, Yasmin Abaza, Christoph Schliemann, Gaurav S Choudhary, Wanying Zhao, Cole Gallagher, Reinhard von Roemeling, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 2924.

https://doi.org/10.1182/blood-2023-190007

Published: 2023

NARROW

Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium

Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients

The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort Study

Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics

Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia

Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia

Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities

Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes

Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia

CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias

Mini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL

Impact of Clinical and Genetic Factors on Myelofibrosis Outcomes after Allogeneic Transplantation

Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

A Phase I Study of Venetoclax in Combination with Inotuzumab Ozogamicin for Relapsed or Refractory ALL in Adults

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Acute Myeloid Leukemia Patients with FLT3 Mutation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only